Development of cataract at · adults with centre‐involving diabetic macular oedema
Summary of findings: intravitreal anti‐VEGF plus intravitreal steroid probably leads to higher development of cataract at compared with intravitreal anti‐VEGF (moderate certainty).
1 finding from 1 review
Development of cataract at · adults with centre‐involving diabetic macular oedema
It is very uncertain whether summary of findings: intravitreal bevacizumab plus intravitreal… changes development of cataract at compared with macular laser (very low certainty).
1 finding from 1 review
Development of cataract at · adults with centre‐involving diabetic macular oedema
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Visual acuity · children younger than two years of age with bilateral congenital cataracts
1 finding from 1 review
Visual axis opacification · children younger than two years of age with bilateral congenital cataracts
It is very uncertain whether summary of findings table ‐ Pseudophakia changes visual axis opacification compared with aphakia (very low certainty).
1 finding from 1 review
Amblyopia ‐ not reported · children younger than two years of age with bilateral congenital cataracts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Glaucoma at 5 years · children younger than two years of age with bilateral congenital cataracts
It is very uncertain whether summary of findings table ‐ Pseudophakia changes glaucoma at 5 years compared with aphakia (very low certainty).
1 finding from 1 review
Retinal detachment ‐ not reported · children younger than two years of age with bilateral congenital cataracts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reoperation rate ‐ not reported · children younger than two years of age with bilateral congenital cataracts
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · children younger than two years of age with bilateral congenital cataracts
1 finding from 1 review
Intraocular inflammation measured by anterior chamber cell and flare 1 week · people who received phacoemulsification
1 finding from 1 review
Intraocular inflammation measured by proportion of participants with corneal edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs showed no clear difference in intraocular inflammation measured by proportion of participants with… compared with corticosteroids (low certainty).
1 finding from 1 review
Proportion of participants with best‐corrected visual acuity of 20/40 1 week · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with cystoid macular edema 1 week · people who received phacoemulsification
Summary of findings for NSAIDs may leads to lower proportion of participants with cystoid macular edema 1 week compared with corticosteroids (low certainty).
1 finding from 1 review
Time to cessation of treatment · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Economic outcomes · people who received phacoemulsification
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in mean change in visual acuity at 1 year (number of letters) compared with ranibizumab (high certainty).
1 finding from 1 review
Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in reduction in central retinal thickness at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review